HGF and metabolic dysfunction-associated steatohepatitis: While this work primarily focuses on the therapeutic potential of Fc(mML1)B3 in the hepatic manifestations of NASH, LG-based HGF mimetics offer promise as a treatment option for several diseases that have been identified as potential targets for recombinant HGF, including amyotrophic lateral sclerosis.20